Oral Weight-Loss Pill Helps Sleep Apnea

Obstructive sleep apnea (OSA) affects millions of adults worldwide, heavily linked to excess body weight. While continuous positive airway pressure (CPAP) machines remain the first-line treatment, patient compliance is often challenging. Recent clinical trial results published in JAMA point toward a promising new oral alternative: orforglipron, an investigational oral GLP-1 receptor agonist.

Researchers evaluated over 700 adults with moderate-to-severe sleep apnea and obesity across two trials, comparing the oral pill against a placebo over 52 weeks.

Key Findings from the Clinical Trials

Bullet Reduced Breathing Disruptions: Patients taking orforglipron experienced roughly 17 fewer breathing stops or significant obstructions per hour during sleep compared to the control group.

Bullet Significant Weight Loss: Participants taking the oral medication achieved an average body weight reduction of a little over 10%, compared to just 1% to 2% in the placebo groups.

Bullet An Oral Alternative: Unlike injectable GLP-1 therapies (such as tirzepatide), orforglipron offers a daily tablet format, which may help patients who experience needle phobia or prefer oral medications.

Bullet Mild-to-Moderate Side Effects: Gastrointestinal side effects were common, affecting about 70% of participants taking the drug, aligning with known profiles of similar GLP-1 treatments.

Clinical Perspective

While the results mark an exciting step forward in combining weight management with sleep apnea care, specialists emphasize that CPAP remains the primary gold standard for severe cases. However, oral therapies like orforglipron could soon offer a powerful complementary tool for individualized patient care.

Source: Medscape